$DVA
DAVITA INC.

2019 Q4 Form 10-Q Financial Statement

#000092706619000176 Filed on November 07, 2019

View on sec.gov

Income Statement

Concept 2019 Q4 2019 Q3 2018 Q4
Revenue $2.899B $2.904B $2.821B
YoY Change 2.75% 1.99% 1.45%
Cost Of Revenue $2.001B $1.991B $2.027B
YoY Change -1.31% -3.52% 4.4%
Gross Profit $898.0M $912.9M $794.1M
YoY Change 13.08% 16.5% -5.37%
Gross Profit Margin 30.98% 31.44% 28.15%
Selling, General & Admin $278.4M $298.7M $268.5M
YoY Change 3.69% -11.39% 3.35%
% of Gross Profit 31.0% 32.72% 33.81%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $158.5M $155.9M $155.1M
YoY Change 2.19% 6.78% -15.71%
% of Gross Profit 17.65% 17.08% 19.53%
Operating Expenses $436.9M $454.6M $423.7M
YoY Change 3.12% -5.9% 4.85%
Operating Profit $462.6M $378.3M $387.9M
YoY Change 19.25% 30.89% 158.03%
Interest Expense -$90.60M -$84.70M -$138.9M
YoY Change -34.77% -34.7% 23.8%
% of Operating Profit -19.59% -22.39% -35.81%
Other Income/Expense, Net $11.50M $5.280M -$500.0K
YoY Change -2400.0% 31.77% -109.09%
Pretax Income $382.0M $273.8M $259.1M
YoY Change 47.43% 63.83% 453.34%
Income Tax $81.70M $65.25M $51.70M
% Of Pretax Income 21.39% 23.83% 19.95%
Net Earnings $244.9M $143.3M -$149.8M
YoY Change -263.5% -204.73% -149.37%
Net Earnings / Revenue 8.45% 4.93% -5.31%
Basic Earnings Per Share $1.89 $0.95 -$0.90
Diluted Earnings Per Share $1.88 $0.95 -$0.90
COMMON SHARES
Basic Shares Outstanding 129.7M shares 150.7M shares 166.0M shares
Diluted Shares Outstanding 151.3M shares

Balance Sheet

Concept 2019 Q4 2019 Q3 2018 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.150B $1.389B $361.4M
YoY Change 218.34% 184.64% -37.56%
Cash & Equivalents $1.102B $1.253B $323.0M
Short-Term Investments $48.09M $135.8M $38.36M
Other Short-Term Assets $173.0M $155.0M $5.594B
YoY Change -96.91% -97.47% 4892.06%
Inventory $97.95M $98.64M $107.4M
Prepaid Expenses $108.3M
Receivables $1.796B $1.901B $1.859B
Other Receivables $489.7M $474.1M $469.8M
Total Short-Term Assets $3.690B $3.999B $8.424B
YoY Change -56.2% -55.22% -3.95%
LONG-TERM ASSETS
Property, Plant & Equipment $3.473B $3.419B $3.394B
YoY Change 2.35% 4.38% 7.76%
Goodwill $6.788B $6.766B $6.842B
YoY Change -0.79% 0.94% 3.5%
Intangibles $135.7M $117.7M $118.8M
YoY Change 14.17% 20.55% 4.41%
Long-Term Investments $0.00 $254.0M $0.00
YoY Change
Other Assets $116.0M $114.8M $71.58M
YoY Change 62.01% 50.08% 51.38%
Total Long-Term Assets $13.62B $13.45B $10.69B
YoY Change 27.47% 29.01% 4.73%
TOTAL ASSETS
Total Short-Term Assets $3.690B $3.999B $8.424B
Total Long-Term Assets $13.62B $13.45B $10.69B
Total Assets $17.31B $17.45B $19.11B
YoY Change -9.41% -9.85% 0.72%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $403.8M $332.1M $463.3M
YoY Change -12.83% -27.63% -9.01%
Accrued Expenses $1.039B $1.037B $659.0M
YoY Change 57.66% 64.08% 6.98%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $131.0M $121.0M $1.929B
YoY Change -93.21% -93.22% 983.71%
Total Short-Term Liabilities $2.372B $2.207B $4.891B
YoY Change -51.5% -54.55% 59.45%
LONG-TERM LIABILITIES
Long-Term Debt $7.978B $8.014B $8.173B
YoY Change -2.39% -5.06% -10.76%
Other Long-Term Liabilities $160.8M $135.1M $450.7M
YoY Change -64.32% -70.14% 23.36%
Total Long-Term Liabilities $160.8M $135.1M $450.7M
YoY Change -64.32% -70.14% 23.36%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.372B $2.207B $4.891B
Total Long-Term Liabilities $160.8M $135.1M $450.7M
Total Liabilities $13.81B $13.64B $14.08B
YoY Change -1.89% -4.35% 7.65%
SHAREHOLDERS EQUITY
Retained Earnings $1.432B $3.349B $2.743B
YoY Change -47.81% -15.24% -24.51%
Common Stock $749.2M $907.2M $995.2M
YoY Change -24.72% -14.1% -4.59%
Preferred Stock
YoY Change
Treasury Stock (at cost) $0.00 $1.860B $0.00
YoY Change 61.26%
Treasury Stock Shares
Shareholders Equity $2.133B $2.319B $3.703B
YoY Change
Total Liabilities & Shareholders Equity $17.31B $17.45B $19.11B
YoY Change -9.41% -9.85% 0.72%

Cashflow Statement

Concept 2019 Q4 2019 Q3 2018 Q4
OPERATING ACTIVITIES
Net Income $244.9M $143.3M -$149.8M
YoY Change -263.5% -204.73% -149.37%
Depreciation, Depletion And Amortization $158.5M $155.9M $155.1M
YoY Change 2.19% 6.78% -15.71%
Cash From Operating Activities $680.6M $640.7M $419.1M
YoY Change 62.4% 53.65% -12.81%
INVESTING ACTIVITIES
Capital Expenditures -$219.3M $173.3M -$281.4M
YoY Change -22.07% -25.21% 5.99%
Acquisitions
YoY Change
Other Investing Activities $80.70M -$95.40M -$62.80M
YoY Change -228.5% 1603.57% -1112.9%
Cash From Investing Activities -$138.7M -$268.7M -$344.3M
YoY Change -59.72% 13.28% 32.83%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -692.7M -2.693B -202.1M
YoY Change 242.75% 2194.04% -14.55%
NET CHANGE
Cash From Operating Activities 680.6M 640.7M 419.1M
Cash From Investing Activities -138.7M -268.7M -344.3M
Cash From Financing Activities -692.7M -2.693B -202.1M
Net Change In Cash -150.8M -2.321B -127.3M
YoY Change 18.46% -3819.87% 748.67%
FREE CASH FLOW
Cash From Operating Activities $680.6M $640.7M $419.1M
Capital Expenditures -$219.3M $173.3M -$281.4M
Free Cash Flow $899.9M $467.4M $700.5M
YoY Change 28.47% 152.23% -6.12%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
dei Entity Central Index Key
EntityCentralIndexKey
0000927066
dva Percentage Change In Discount Rate Used To Evaluate Fair Value Of Reporting Unit For Goodwill Assessment
PercentageChangeInDiscountRateUsedToEvaluateFairValueOfReportingUnitForGoodwillAssessment
0.0100
CY2019Q3 dva Terminated Remaining Prior Share Repurchases Authorized Amount
TerminatedRemainingPriorShareRepurchasesAuthorizedAmount
1005605000 USD
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
450000000 shares
CY2019Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
450000000 shares
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
166387307 shares
CY2019Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
166540590 shares
dei Entity File Number
EntityFileNumber
1-14106
dei Entity Registrant Name
EntityRegistrantName
DAVITA INC.
dei Trading Symbol
TradingSymbol
DVA
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
166387307 shares
dei Security Exchange Name
SecurityExchangeName
NYSE
dei Document Transition Report
DocumentTransitionReport
false
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
CY2019Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
133888864 shares
CY2018Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
80566000 USD
CY2019Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
78437000 USD
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2019Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2019Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2018Q4 us-gaap Property Plant And Equipment Owned Accumulated Depreciation
PropertyPlantAndEquipmentOwnedAccumulatedDepreciation
3524098000 USD
CY2019Q3 us-gaap Property Plant And Equipment Owned Accumulated Depreciation
PropertyPlantAndEquipmentOwnedAccumulatedDepreciation
3792683000 USD
CY2018Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
0 shares
CY2019Q3 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
32651726 shares
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2019-09-30
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
51-0354549
dei Entity Address Address Line1
EntityAddressAddressLine1
2000 16th Street
dei Entity Address City Or Town
EntityAddressCityOrTown
Denver,
dei Entity Address State Or Province
EntityAddressStateOrProvince
CO
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
80202
dei City Area Code
CityAreaCode
720
dei Local Phone Number
LocalPhoneNumber
631-2100
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2019Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
129700000 shares
CY2019Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
2781169000 USD
CY2018Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
2670701000 USD
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
8150386000 USD
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
7980178000 USD
us-gaap Revenues
Revenues
8489895000 USD
us-gaap Revenues
Revenues
8583727000 USD
CY2019Q3 dva Patient Care Costs
PatientCareCosts
1991172000 USD
CY2018Q3 dva Patient Care Costs
PatientCareCosts
2063770000 USD
dva Patient Care Costs
PatientCareCosts
5913860000 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
456685000 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
435878000 USD
CY2019Q3 us-gaap Health Care Organization Patient Service Revenue Provisionfor Bad Debts
HealthCareOrganizationPatientServiceRevenueProvisionforBadDebts
3977000 USD
CY2018Q3 us-gaap Health Care Organization Patient Service Revenue Provisionfor Bad Debts
HealthCareOrganizationPatientServiceRevenueProvisionforBadDebts
11977000 USD
us-gaap Health Care Organization Patient Service Revenue Provisionfor Bad Debts
HealthCareOrganizationPatientServiceRevenueProvisionforBadDebts
19689000 USD
us-gaap Health Care Organization Patient Service Revenue Provisionfor Bad Debts
HealthCareOrganizationPatientServiceRevenueProvisionforBadDebts
35838000 USD
CY2019Q3 us-gaap Health Care Organization Patient Service Revenue Less Provision For Bad Debts
HealthCareOrganizationPatientServiceRevenueLessProvisionForBadDebts
2777192000 USD
CY2018Q3 us-gaap Health Care Organization Patient Service Revenue Less Provision For Bad Debts
HealthCareOrganizationPatientServiceRevenueLessProvisionForBadDebts
2658724000 USD
us-gaap Health Care Organization Patient Service Revenue Less Provision For Bad Debts
HealthCareOrganizationPatientServiceRevenueLessProvisionForBadDebts
8130697000 USD
us-gaap Health Care Organization Patient Service Revenue Less Provision For Bad Debts
HealthCareOrganizationPatientServiceRevenueLessProvisionForBadDebts
7944340000 USD
CY2019Q3 us-gaap Other Income
OtherIncome
126886000 USD
CY2018Q3 us-gaap Other Income
OtherIncome
188606000 USD
us-gaap Other Income
OtherIncome
359198000 USD
us-gaap Other Income
OtherIncome
639387000 USD
CY2019Q3 us-gaap Revenues
Revenues
2904078000 USD
CY2018Q3 us-gaap Revenues
Revenues
2847330000 USD
dva Patient Care Costs
PatientCareCosts
6168444000 USD
CY2019Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
298736000 USD
CY2018Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
336299000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
824887000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
866922000 USD
CY2019Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
155915000 USD
CY2018Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
146000000 USD
CY2019Q3 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0 USD
CY2018Q3 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
800000 USD
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0 USD
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-7300000 USD
CY2019Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
3936000 USD
CY2018Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-3824000 USD
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
11158000 USD
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
6126000 USD
CY2019Q3 us-gaap Other Asset Impairment Charges
OtherAssetImpairmentCharges
0 USD
CY2018Q3 us-gaap Other Asset Impairment Charges
OtherAssetImpairmentCharges
6093000 USD
us-gaap Other Asset Impairment Charges
OtherAssetImpairmentCharges
0 USD
us-gaap Other Asset Impairment Charges
OtherAssetImpairmentCharges
17338000 USD
CY2019Q3 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
83855000 USD
CY2018Q3 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 USD
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
124892000 USD
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
3106000 USD
CY2019Q3 us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
0 USD
CY2018Q3 us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
-1506000 USD
us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
0 USD
us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
32451000 USD
CY2019Q3 us-gaap Costs And Expenses
CostsAndExpenses
2525742000 USD
CY2018Q3 us-gaap Costs And Expenses
CostsAndExpenses
2558292000 USD
us-gaap Costs And Expenses
CostsAndExpenses
7309166000 USD
us-gaap Costs And Expenses
CostsAndExpenses
7445811000 USD
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
378336000 USD
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
289038000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
1180729000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
1137916000 USD
CY2019Q3 us-gaap Interest And Debt Expense
InterestAndDebtExpense
88589000 USD
CY2018Q3 us-gaap Interest And Debt Expense
InterestAndDebtExpense
125927000 USD
us-gaap Interest And Debt Expense
InterestAndDebtExpense
351774000 USD
us-gaap Interest And Debt Expense
InterestAndDebtExpense
359135000 USD
CY2019Q3 dva Debt Prepayment Refinancing Redemption Charges
DebtPrepaymentRefinancingRedemptionCharges
21242000 USD
CY2018Q3 dva Debt Prepayment Refinancing Redemption Charges
DebtPrepaymentRefinancingRedemptionCharges
0 USD
dva Debt Prepayment Refinancing Redemption Charges
DebtPrepaymentRefinancingRedemptionCharges
33402000 USD
dva Debt Prepayment Refinancing Redemption Charges
DebtPrepaymentRefinancingRedemptionCharges
0 USD
CY2019Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
5280000 USD
CY2018Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4007000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
17863000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
10583000 USD
CY2019Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
273785000 USD
CY2018Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
167118000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
813416000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
789364000 USD
CY2019Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
65254000 USD
CY2018Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
52047000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
197938000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
206652000 USD
CY2019Q3 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
208531000 USD
CY2018Q3 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
115071000 USD
us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
615478000 USD
us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
582712000 USD
CY2019Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-6843000 USD
CY2018Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-211739000 USD
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
102854000 USD
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-147829000 USD
CY2019Q3 us-gaap Profit Loss
ProfitLoss
201688000 USD
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
2.66
CY2018Q3 us-gaap Profit Loss
ProfitLoss
-96668000 USD
us-gaap Profit Loss
ProfitLoss
718332000 USD
us-gaap Profit Loss
ProfitLoss
434883000 USD
CY2019Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
58418000 USD
CY2018Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
40128000 USD
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
152222000 USD
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
125717000 USD
CY2019Q3 us-gaap Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest
NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
143270000 USD
CY2018Q3 us-gaap Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest
NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
-136796000 USD
us-gaap Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest
NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
566110000 USD
us-gaap Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest
NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
309166000 USD
CY2019Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
1.00
CY2018Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
0.44
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
2.88
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
2.69
CY2019Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.95
CY2018Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.82
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.51
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.79
CY2019Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
0.99
CY2018Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
0.44
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
2.87
CY2019Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.95
CY2018Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.82
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.50
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.77
CY2019Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
150675465 shares
CY2018Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
166770664 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
161147122 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
172403944 shares
CY2019Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
151295950 shares
CY2018Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
167262358 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
161636011 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
174348421 shares
CY2019Q3 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
150113000 USD
CY2018Q3 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
73371000 USD
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
464590000 USD
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
463989000 USD
CY2019Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
-6843000 USD
CY2018Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
-210167000 USD
us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
101520000 USD
us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
-154823000 USD
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
143270000 USD
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-136796000 USD
us-gaap Net Income Loss
NetIncomeLoss
566110000 USD
us-gaap Net Income Loss
NetIncomeLoss
309166000 USD
CY2019Q3 us-gaap Profit Loss
ProfitLoss
201688000 USD
CY2018Q3 us-gaap Profit Loss
ProfitLoss
-96668000 USD
us-gaap Profit Loss
ProfitLoss
718332000 USD
us-gaap Profit Loss
ProfitLoss
434883000 USD
CY2019Q3 us-gaap Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax
-1060000 USD
CY2018Q3 us-gaap Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax
37000 USD
us-gaap Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax
-1672000 USD
us-gaap Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax
819000 USD
CY2019Q3 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax
-1569000 USD
CY2018Q3 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax
-1606000 USD
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax
-4782000 USD
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax
-4680000 USD
CY2019Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-44502000 USD
CY2018Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-8827000 USD
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-45790000 USD
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-39475000 USD
CY2019Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-43993000 USD
CY2018Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-7184000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-42680000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-33976000 USD
CY2019Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
157695000 USD
CY2018Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-103852000 USD
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
675652000 USD
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
400907000 USD
CY2019Q3 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
58418000 USD
CY2018Q3 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
40128000 USD
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
152222000 USD
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
125717000 USD
CY2019Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
99277000 USD
CY2018Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-143980000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
523430000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
275190000 USD
CY2019Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1253256000 USD
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
323038000 USD
CY2019Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
103885000 USD
CY2019Q3 us-gaap Inventory Net
InventoryNet
98641000 USD
CY2018Q4 us-gaap Inventory Net
InventoryNet
107381000 USD
CY2019Q3 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
474145000 USD
CY2018Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
469796000 USD
CY2019Q3 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
16236000 USD
CY2018Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
68614000 USD
CY2019Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
50617000 USD
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
111840000 USD
CY2019Q3 us-gaap Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
0 USD
CY2018Q4 us-gaap Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
5389565000 USD
CY2018Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
92382000 USD
CY2019Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
100713000 USD
CY2018Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
2935000 USD
CY2019Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1901225000 USD
CY2018Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1858608000 USD
CY2019Q3 us-gaap Assets Current
AssetsCurrent
3998718000 USD
CY2018Q4 us-gaap Assets Current
AssetsCurrent
8424159000 USD
CY2019Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3419238000 USD
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3393669000 USD
CY2019Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2781288000 USD
CY2018Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
0 USD
CY2019Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
117666000 USD
CY2018Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
118846000 USD
CY2019Q3 us-gaap Investments In Affiliates Subsidiaries Associates And Joint Ventures
InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
219386000 USD
CY2018Q4 us-gaap Investments In Affiliates Subsidiaries Associates And Joint Ventures
InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
224611000 USD
CY2019Q3 us-gaap Long Term Investments
LongTermInvestments
35041000 USD
CY2018Q4 us-gaap Long Term Investments
LongTermInvestments
35424000 USD
CY2019Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
114834000 USD
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
71583000 USD
CY2019Q3 us-gaap Goodwill
Goodwill
6765659000 USD
CY2018Q4 us-gaap Goodwill
Goodwill
6841960000 USD
CY2019Q3 us-gaap Assets
Assets
17451830000 USD
CY2018Q4 us-gaap Assets
Assets
19110252000 USD
CY2019Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
332136000 USD
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
463270000 USD
CY2019Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
716023000 USD
CY2018Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
595850000 USD
CY2019Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
662826000 USD
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
658913000 USD
CY2019Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
374214000 USD
CY2018Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
0 USD
CY2019Q3 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
121441000 USD
CY2018Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
1929369000 USD
CY2019Q3 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
0 USD
CY2018Q4 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
1243759000 USD
CY2019Q3 us-gaap Liabilities Current
LiabilitiesCurrent
2206640000 USD
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4891161000 USD
CY2019Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2682125000 USD
CY2018Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0 USD
CY2019Q3 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
8014475000 USD
CY2018Q4 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
8172847000 USD
CY2019Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
135087000 USD
CY2018Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
450669000 USD
CY2019Q3 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
604921000 USD
CY2018Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
562536000 USD
CY2019Q3 us-gaap Liabilities
Liabilities
13643248000 USD
CY2018Q4 us-gaap Liabilities
Liabilities
14077213000 USD
CY2019Q3 us-gaap Redeemable Noncontrolling Interest Equity Carrying Amount
RedeemableNoncontrollingInterestEquityCarryingAmount
1296059000 USD
CY2018Q4 us-gaap Redeemable Noncontrolling Interest Equity Carrying Amount
RedeemableNoncontrollingInterestEquityCarryingAmount
1124641000 USD
CY2019Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2019Q3 us-gaap Common Stock Value
CommonStockValue
167000 USD
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
166000 USD
CY2019Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
906990000 USD
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
995006000 USD
CY2019Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
3349180000 USD
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
2743194000 USD
CY2019Q3 us-gaap Treasury Stock Value
TreasuryStockValue
1860157000 USD
CY2018Q4 us-gaap Treasury Stock Value
TreasuryStockValue
0 USD
CY2019Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-77604000 USD
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-34924000 USD
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
2318576000 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
3703442000 USD
CY2019Q3 us-gaap Minority Interest
MinorityInterest
193947000 USD
CY2018Q4 us-gaap Minority Interest
MinorityInterest
204956000 USD
CY2019Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
2512523000 USD
CY2018Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
3908398000 USD
CY2019Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
17451830000 USD
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
19110252000 USD
us-gaap Profit Loss
ProfitLoss
718332000 USD
us-gaap Profit Loss
ProfitLoss
434883000 USD
us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
456685000 USD
us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
435878000 USD
us-gaap Goodwill And Intangible Asset Impairment
GoodwillAndIntangibleAssetImpairment
124892000 USD
us-gaap Goodwill And Intangible Asset Impairment
GoodwillAndIntangibleAssetImpairment
20444000 USD
dva Debt Prepayment Refinancing Redemption Charges
DebtPrepaymentRefinancingRedemptionCharges
33402000 USD
dva Debt Prepayment Refinancing Redemption Charges
DebtPrepaymentRefinancingRedemptionCharges
0 USD
us-gaap Share Based Compensation
ShareBasedCompensation
47811000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
59605000 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
72590000 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
200056000 USD
dva Adjustment Income Loss From Equity Method Investments
AdjustmentIncomeLossFromEquityMethodInvestments
-5131000 USD
dva Adjustment Income Loss From Equity Method Investments
AdjustmentIncomeLossFromEquityMethodInvestments
-8611000 USD
dva Gain Loss On Sale Of Business Including Activity From Discontinued Operations
GainLossOnSaleOfBusinessIncludingActivityFromDiscontinuedOperations
-23022000 USD
dva Gain Loss On Sale Of Business Including Activity From Discontinued Operations
GainLossOnSaleOfBusinessIncludingActivityFromDiscontinuedOperations
57547000 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-24291000 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-164856000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
182684000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
74622000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-9519000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-88355000 USD
dva Increase Decrease In Other Current Receivables And Other Current Assets
IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets
-51319000 USD
dva Increase Decrease In Other Current Receivables And Other Current Assets
IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets
757000 USD
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-2324000 USD
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-2142000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-106662000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-12800000 USD
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-57930000 USD
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
40225000 USD
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
140046000 USD
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
45624000 USD
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
57279000 USD
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
21749000 USD
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-27542000 USD
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
5546000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
1391825000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
1382248000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
547183000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
705659000 USD
us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
77348000 USD
us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
113526000 USD
us-gaap Proceeds From Sales Of Business Affiliate And Productive Assets
ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets
3863619000 USD
us-gaap Proceeds From Sales Of Business Affiliate And Productive Assets
ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets
135268000 USD
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
5160000 USD
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
5791000 USD
us-gaap Payments To Acquire Held To Maturity Securities
PaymentsToAcquireHeldToMaturitySecurities
98322000 USD
us-gaap Payments To Acquire Held To Maturity Securities
PaymentsToAcquireHeldToMaturitySecurities
3728000 USD
us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
5893000 USD
us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
8783000 USD
us-gaap Proceeds From Sale And Maturity Of Held To Maturity Securities
ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities
0 USD
us-gaap Proceeds From Sale And Maturity Of Held To Maturity Securities
ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities
32628000 USD
us-gaap Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
8770000 USD
us-gaap Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
12874000 USD
us-gaap Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital
ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
1296000 USD
us-gaap Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital
ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
3580000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
3134025000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-661319000 USD
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
38519991000 USD
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
41674279000 USD
us-gaap Repayments Of Debt And Capital Lease Obligations
RepaymentsOfDebtAndCapitalLeaseObligations
40570003000 USD
us-gaap Repayments Of Debt And Capital Lease Obligations
RepaymentsOfDebtAndCapitalLeaseObligations
40828443000 USD
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
1837022000 USD
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
1161511000 USD
us-gaap Payments Of Distributions To Affiliates
PaymentsOfDistributionsToAffiliates
157170000 USD
us-gaap Payments Of Distributions To Affiliates
PaymentsOfDistributionsToAffiliates
139673000 USD
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
7333000 USD
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
8803000 USD
us-gaap Proceeds From Contributions From Affiliates
ProceedsFromContributionsFromAffiliates
44095000 USD
us-gaap Proceeds From Contributions From Affiliates
ProceedsFromContributionsFromAffiliates
43179000 USD
us-gaap Proceeds From Minority Shareholders
ProceedsFromMinorityShareholders
0 USD
us-gaap Proceeds From Minority Shareholders
ProceedsFromMinorityShareholders
15000 USD
us-gaap Payments To Minority Shareholders
PaymentsToMinorityShareholders
10988000 USD
us-gaap Payments To Minority Shareholders
PaymentsToMinorityShareholders
19988000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-4003764000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-423339000 USD
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-4178000 USD
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-5790000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
517908000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
291800000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
415420000 USD
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
518920000 USD
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1357141000 USD
CY2018Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
540155000 USD
CY2019Q3 us-gaap Revenues
Revenues
2904078000 USD
CY2018Q3 us-gaap Revenues
Revenues
2847330000 USD
us-gaap Revenues
Revenues
8489895000 USD
us-gaap Revenues
Revenues
8583727000 USD
CY2019Q3 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
15090000 USD
CY2018Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
52924000 USD
CY2019Q3 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
150113000 USD
CY2018Q3 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
73371000 USD
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
464590000 USD
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
463989000 USD
CY2019Q3 us-gaap Minority Interest Change In Redemption Value
MinorityInterestChangeInRedemptionValue
0 USD
CY2018Q3 us-gaap Minority Interest Change In Redemption Value
MinorityInterestChangeInRedemptionValue
98000 USD
us-gaap Minority Interest Change In Redemption Value
MinorityInterestChangeInRedemptionValue
0 USD
us-gaap Minority Interest Change In Redemption Value
MinorityInterestChangeInRedemptionValue
0 USD
CY2019Q3 dva Income Loss From Continuing Operations Available To Common Stockholders Basic
IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic
150113000 USD
CY2018Q3 dva Income Loss From Continuing Operations Available To Common Stockholders Basic
IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic
73469000 USD
dva Income Loss From Continuing Operations Available To Common Stockholders Basic
IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic
464590000 USD
dva Income Loss From Continuing Operations Available To Common Stockholders Basic
IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic
463989000 USD
CY2019Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
-6843000 USD
CY2018Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
-210167000 USD
us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
101520000 USD
us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
-154823000 USD
CY2019Q3 dva Income Loss From Continuing Operations Attributableto Parent Available To Common Stockholders Basic
IncomeLossFromContinuingOperationsAttributabletoParentAvailableToCommonStockholdersBasic
143270000 USD
dva Income Loss From Continuing Operations Attributableto Parent Available To Common Stockholders Basic
IncomeLossFromContinuingOperationsAttributabletoParentAvailableToCommonStockholdersBasic
309166000 USD
CY2018Q3 dva Income Loss From Continuing Operations Attributableto Parent Available To Common Stockholders Basic
IncomeLossFromContinuingOperationsAttributabletoParentAvailableToCommonStockholdersBasic
-136698000 USD
dva Income Loss From Continuing Operations Attributableto Parent Available To Common Stockholders Basic
IncomeLossFromContinuingOperationsAttributabletoParentAvailableToCommonStockholdersBasic
566110000 USD
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
174348000 shares
CY2019Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
0.99
CY2018Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
0.44
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
2.87
CY2019Q3 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
150675000 shares
CY2018Q3 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
166819000 shares
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
161147000 shares
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
2.66
CY2019Q3 us-gaap Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share
DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare
-0.04
CY2018Q3 us-gaap Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share
DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare
-1.26
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-0.63
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0.90
CY2019Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.95
CY2018Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.82
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.51
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.79
CY2019Q3 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
150675000 shares
CY2018Q3 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
166819000 shares
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
161147000 shares
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
173875000 shares
CY2019Q3 us-gaap Weighted Average Number Of Shares Contingently Issuable
WeightedAverageNumberOfSharesContingentlyIssuable
0 shares
CY2018Q3 us-gaap Weighted Average Number Of Shares Contingently Issuable
WeightedAverageNumberOfSharesContingentlyIssuable
48000 shares
us-gaap Weighted Average Number Of Shares Contingently Issuable
WeightedAverageNumberOfSharesContingentlyIssuable
0 shares
us-gaap Weighted Average Number Of Shares Contingently Issuable
WeightedAverageNumberOfSharesContingentlyIssuable
1471000 shares
CY2019Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
150675000 shares
CY2018Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
166771000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
161147000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
172404000 shares
CY2019Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
1.00
CY2018Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
0.44
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
2.88
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
2.69
CY2019Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0.05
CY2018Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
1.26
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
173875000 shares
CY2019Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
621000 shares
CY2018Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
443000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
489000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
473000 shares
CY2019Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
151296000 shares
CY2018Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
167262000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
161636000 shares
us-gaap Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share
DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare
0.63
us-gaap Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share
DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare
-0.89
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.50
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.77
CY2018Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.82
CY2019Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.95
CY2019Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7293000 shares
CY2018Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5281000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6414000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4987000 shares
CY2019Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
103885000 USD
CY2018Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
92382000 USD
CY2019Q3 us-gaap Held To Maturity Securities
HeldToMaturitySecurities
98113000 USD
CY2019Q3 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
37641000 USD
CY2019Q3 us-gaap Marketable Securities
MarketableSecurities
135754000 USD
CY2018Q4 us-gaap Held To Maturity Securities
HeldToMaturitySecurities
2235000 USD
CY2018Q4 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
36124000 USD
CY2018Q4 us-gaap Marketable Securities
MarketableSecurities
38359000 USD
CY2019Q3 us-gaap Held To Maturity Securities Current
HeldToMaturitySecuritiesCurrent
98113000 USD
CY2019Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
100713000 USD
CY2018Q4 us-gaap Held To Maturity Securities Current
HeldToMaturitySecuritiesCurrent
2235000 USD
CY2018Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
2935000 USD
CY2019Q3 us-gaap Held To Maturity Securities Noncurrent
HeldToMaturitySecuritiesNoncurrent
0 USD
CY2019Q3 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
35041000 USD
CY2018Q4 us-gaap Held To Maturity Securities Noncurrent
HeldToMaturitySecuritiesNoncurrent
0 USD
CY2018Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
35424000 USD
CY2019Q3 us-gaap Held To Maturity Securities
HeldToMaturitySecurities
98113000 USD
CY2019Q3 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
37641000 USD
CY2019Q3 us-gaap Marketable Securities
MarketableSecurities
135754000 USD
CY2018Q4 us-gaap Held To Maturity Securities
HeldToMaturitySecurities
2235000 USD
CY2018Q4 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
36124000 USD
CY2018Q4 us-gaap Marketable Securities
MarketableSecurities
38359000 USD
CY2019Q3 us-gaap Investments In Affiliates Subsidiaries Associates And Joint Ventures
InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
219386000 USD
CY2018Q4 us-gaap Investments In Affiliates Subsidiaries Associates And Joint Ventures
InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
224611000 USD
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
11158000 USD
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
6126000 USD
CY2019Q3 dva Partnership Capital Contribution Scheduled Date
PartnershipCapitalContributionScheduledDate
2019-08-01
dva Valuation Adjustment
ValuationAdjustment
1938000 USD
dva Valuation Adjustment
ValuationAdjustment
0 USD
CY2017Q4 us-gaap Goodwill
Goodwill
6610279000 USD
CY2018 us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
278348000 USD
CY2018 us-gaap Goodwill Written Off Related To Sale Of Business Unit
GoodwillWrittenOffRelatedToSaleOfBusinessUnit
15497000 USD
CY2018 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
3106000 USD
CY2018 us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
28064000 USD
CY2018Q4 us-gaap Goodwill
Goodwill
6841960000 USD
us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
77238000 USD
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
124892000 USD
us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
28647000 USD
CY2019Q3 us-gaap Goodwill
Goodwill
6765659000 USD
CY2019Q3 us-gaap Goodwill Gross
GoodwillGross
6915400000 USD
CY2019Q3 us-gaap Goodwill Impaired Accumulated Impairment Loss
GoodwillImpairedAccumulatedImpairmentLoss
149741000 USD
CY2019Q3 us-gaap Goodwill
Goodwill
6765659000 USD
CY2019Q3 us-gaap Goodwill Subsequent Recognition Of Deferred Tax Asset
GoodwillSubsequentRecognitionOfDeferredTaxAsset
17769000 USD
CY2019Q3 us-gaap Goodwill Impairment Loss Net Of Tax
GoodwillImpairmentLossNetOfTax
66086000 USD
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
124892000 USD
dva Percentage Change In Operating Income Used To Evaluate Fair Value Of Reporting Unit For Goodwill Assessment
PercentageChangeInOperatingIncomeUsedToEvaluateFairValueOfReportingUnitForGoodwillAssessment
0.03
CY2019Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
52769000 USD
CY2019Q3 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
49926000 USD
us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
12387000 USD
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
40382000 USD
CY2019Q3 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
11292000 USD
CY2018Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
9019000 USD
CY2019Q3 dva Acquisition Obligations And Other Notes Payable
AcquisitionObligationsAndOtherNotesPayable
181757000 USD
CY2018Q4 dva Acquisition Obligations And Other Notes Payable
AcquisitionObligationsAndOtherNotesPayable
183979000 USD
CY2019Q3 dva Acquisition Obligations And Other Notes Payable
AcquisitionObligationsAndOtherNotesPayable
181757000 USD
CY2019Q3 us-gaap Finance Lease Liability
FinanceLeaseLiability
280138000 USD
CY2018Q4 us-gaap Finance Lease Liability
FinanceLeaseLiability
282737000 USD
CY2019Q3 us-gaap Finance Lease Liability
FinanceLeaseLiability
280138000 USD
CY2019Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
8211895000 USD
CY2018Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
10154216000 USD
CY2019Q3 dva Discount And Deferred Finance Costs
DiscountAndDeferredFinanceCosts
75979000 USD
CY2018Q4 dva Discount And Deferred Finance Costs
DiscountAndDeferredFinanceCosts
52000000 USD
CY2019Q3 us-gaap Long Term Debt And Capital Lease Obligations Including Current Maturities
LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities
8135916000 USD
CY2018Q4 us-gaap Long Term Debt And Capital Lease Obligations Including Current Maturities
LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities
10102216000 USD
CY2019Q3 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
121441000 USD
CY2018Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
1929369000 USD
CY2019Q3 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
8014475000 USD
CY2018Q4 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
8172847000 USD
CY2019Q2 dva Long Term Debt Maturity Extension Term
LongTermDebtMaturityExtensionTerm
P6M
CY2019Q3 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
29841000 USD
CY2019Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
129082000 USD
CY2019Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
153120000 USD
CY2019Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
168824000 USD
CY2019Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
224455000 USD
CY2019Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
3171804000 USD
CY2019Q3 us-gaap Long Term Debt Maturities Repayments Of Principal After Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
4334769000 USD
CY2019Q3 dva Debt Prepayment Refinancing Redemption Charges
DebtPrepaymentRefinancingRedemptionCharges
21242000 USD
dva Debt Prepayment Refinancing Redemption Charges
DebtPrepaymentRefinancingRedemptionCharges
33402000 USD
CY2019Q3 dva Debt Prepayment Refinancing Redemption Charges
DebtPrepaymentRefinancingRedemptionCharges
21242000 USD
CY2019Q2 dva Accelerated Amortization Of Debt Discount And Deferred Financing Costs
AcceleratedAmortizationOfDebtDiscountAndDeferredFinancingCosts
12160000 USD
CY2019Q3 us-gaap Debt Instrument Interest Rate During Period
DebtInstrumentInterestRateDuringPeriod
0.0509
us-gaap Debt Instrument Interest Rate During Period
DebtInstrumentInterestRateDuringPeriod
0.0514
CY2019Q3 us-gaap Longterm Debt Weighted Average Interest Rate
LongtermDebtWeightedAverageInterestRate
0.0466
CY2019Q3 us-gaap Long Term Debt Percentage Bearing Fixed Interest Rate
LongTermDebtPercentageBearingFixedInterestRate
0.4403
CY2019Q3 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
59723000 USD
CY2019Q3 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
254967000 USD
CY2018Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
367164000 USD
CY2019Q3 dva Finance Lease Accumulated Depreciation
FinanceLeaseAccumulatedDepreciation
21606000 USD
CY2018Q4 dva Finance Lease Accumulated Depreciation
FinanceLeaseAccumulatedDepreciation
131971000 USD
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
474292000 USD
CY2019Q3 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
33950000 USD
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
437481000 USD
CY2019Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
133342000 USD
us-gaap Operating Lease Expense
OperatingLeaseExpense
392398000 USD
CY2019Q3 us-gaap Variable Lease Cost
VariableLeaseCost
30786000 USD
us-gaap Variable Lease Cost
VariableLeaseCost
89264000 USD
CY2019Q3 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
6164000 USD
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
17693000 USD
CY2019Q3 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
3803000 USD
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
11293000 USD
CY2019Q3 us-gaap Lease Cost
LeaseCost
174095000 USD
us-gaap Lease Cost
LeaseCost
510648000 USD
CY2019Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9Y1M6D
CY2019Q3 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P10Y6M
CY2019Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.042
us-gaap Sale And Leaseback Transaction Gain Loss Net
SaleAndLeasebackTransactionGainLossNet
13903000 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
467338000 USD
us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
16226000 USD
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
21905000 USD
dva Net Operating Lease Assets Obtained In Exchange For Lease Liabilities
NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities
299697000 USD
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
121795000 USD
CY2019Q3 us-gaap Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
8384000 USD
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
497654000 USD
CY2019Q3 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
38411000 USD
CY2019Q3 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
34369000 USD
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
390993000 USD
CY2019Q3 us-gaap Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
34511000 USD
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
340662000 USD
CY2019Q3 us-gaap Finance Lease Liability Payments Due Year Five
FinanceLeaseLiabilityPaymentsDueYearFive
34540000 USD
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
1433145000 USD
CY2019Q3 us-gaap Finance Lease Liability Payments Due After Year Five
FinanceLeaseLiabilityPaymentsDueAfterYearFive
183786000 USD
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
3696022000 USD
CY2019Q3 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
367951000 USD
CY2019Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
639683000 USD
CY2019Q3 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
87813000 USD
CY2019Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
3056339000 USD
CY2019Q3 us-gaap Finance Lease Liability
FinanceLeaseLiability
280138000 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
483488000 USD
CY2018Q4 us-gaap Capital Leases Future Minimum Payments Due Current
CapitalLeasesFutureMinimumPaymentsDueCurrent
36754000 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
462154000 USD
CY2018Q4 us-gaap Capital Leases Future Minimum Payments Due In Two Years
CapitalLeasesFutureMinimumPaymentsDueInTwoYears
41044000 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
432950000 USD
CY2018Q4 us-gaap Capital Leases Future Minimum Payments Due In Three Years
CapitalLeasesFutureMinimumPaymentsDueInThreeYears
34026000 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
395462000 USD
CY2018Q4 us-gaap Capital Leases Future Minimum Payments Due In Four Years
CapitalLeasesFutureMinimumPaymentsDueInFourYears
33690000 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
349649000 USD
CY2018Q4 us-gaap Capital Leases Future Minimum Payments Due In Five Years
CapitalLeasesFutureMinimumPaymentsDueInFiveYears
33845000 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
1589949000 USD
CY2018Q4 us-gaap Capital Leases Future Minimum Payments Due Thereafter
CapitalLeasesFutureMinimumPaymentsDueThereafter
194611000 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
3713652000 USD
CY2018Q4 us-gaap Capital Leases Future Minimum Payments Due
CapitalLeasesFutureMinimumPaymentsDue
373970000 USD
CY2018Q4 us-gaap Capital Leases Future Minimum Payments Interest Included In Payments
CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments
91233000 USD
CY2018Q4 us-gaap Capital Leases Future Minimum Payments Present Value Of Net Minimum Payments
CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments
282737000 USD
us-gaap Loss Contingency Disclosures
LossContingencyDisclosures
<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Contingencies</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The majority of the Company’s revenues are from government programs and may be subject to adjustment as a result of: (i) examination by government agencies or contractors, for which the resolution of any matters raised may take extended periods of time to finalize; (ii) differing interpretations of government regulations by different Medicare contractors or regulatory authorities; (iii) differing opinions regarding a patient’s medical diagnosis or the medical necessity of services provided; and (iv) retroactive applications or interpretations of governmental requirements. In addition, the Company’s revenues from commercial payors may be subject to adjustment as a result of potential claims for refunds, as a result of government actions or as a result of other claims by commercial payors.</span></div><div style="line-height:120%;padding-top:12px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company operates in a highly regulated industry and is a party to various lawsuits, demands, claims, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">qui tam</span><span style="font-family:inherit;font-size:10pt;"> suits, governmental investigations and audits (including, without limitation, investigations or other actions resulting from its obligation to self-report suspected violations of law) and other legal proceedings. The Company records accruals for certain legal proceedings and regulatory matters to the extent that the Company determines an unfavorable outcome is probable and the amount of the loss can be reasonably estimated. As of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, the Company’s total recorded accruals with respect to legal proceedings and regulatory matters, net of anticipated third party recoveries, were immaterial. While these accruals reflect the Company’s best estimate of the probable loss for those matters as of the dates of those accruals, the recorded amounts may differ materially from the actual amount of the losses for those matters, and any anticipated third party recoveries for any such losses may not ultimately be recoverable. Additionally, in some cases, no estimate of the possible loss or range of loss in excess of amounts accrued, if any, can be made because of the inherently unpredictable nature of legal proceedings and regulatory matters, which also may be impacted by various factors, including, without limitation, that they may involve indeterminate claims for monetary damages or may involve fines, penalties or non-monetary remedies; present novel legal theories or legal uncertainties; involve disputed facts; represent a shift in regulatory policy; are in the early stages of the proceedings; or may result in a change of business practices. Further, there may be various levels of judicial review available to the Company in connection with any such proceeding.</span></div><div style="line-height:120%;padding-top:12px;text-indent:37px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following is a description of certain lawsuits, claims, governmental investigations and audits and other legal proceedings to which the Company is subject.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Governmental Inquiries and Certain Related Proceedings</span></div><div style="line-height:120%;padding-top:12px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">2016 U.S. Attorney Texas Investigation</span><span style="font-family:inherit;font-size:10pt;">: In early February 2016, the Company announced that its pharmacy services' wholly-owned subsidiary, DaVita Rx, LLC (DaVita Rx), received a Civil Investigative Demand (CID) from the U.S. Attorney’s Office, Northern District of Texas. The government is conducting a federal False Claims Act (FCA) investigation concerning allegations that DaVita Rx presented or caused to be presented false claims for payment to the government for prescription medications, as well as an investigation into the Company’s relationships with pharmaceutical manufacturers. The CID covers the period from January 1, 2006 through the present. In connection with the Company’s ongoing efforts working with the government, the Company learned that a </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">qui tam</span><span style="font-family:inherit;font-size:10pt;"> complaint had been filed covering some of the issues in the CID and practices that had been identified by the Company in a self-disclosure filed with the Office of Inspector General (OIG) for the U.S. Department of Health and Human Services (HHS) in February 2016. In December 2017, the Company finalized and executed a settlement agreement with the government and relators in the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">qui tam</span><span style="font-family:inherit;font-size:10pt;"> matter that included total monetary consideration of </span><span style="font-family:inherit;font-size:10pt;"><span>$63,700</span></span><span style="font-family:inherit;font-size:10pt;">, as previously disclosed, of which </span><span style="font-family:inherit;font-size:10pt;"><span>$41,500</span></span><span style="font-family:inherit;font-size:10pt;"> was an incremental cash payment and </span><span style="font-family:inherit;font-size:10pt;"><span>$22,200</span></span><span style="font-family:inherit;font-size:10pt;"> was for amounts previously refunded, and all of which was previously accrued. The government’s investigation into certain of the Company's relationships with pharmaceutical manufacturers is ongoing, and in July 2018 the OIG served the Company with a subpoena seeking additional documents and information relating to those relationships. The Company is continuing to cooperate with the government in this investigation.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">2017 U.S. Attorney Massachusetts Investigation</span><span style="font-family:inherit;font-size:10pt;">: In January 2017, the Company was served with an administrative subpoena for records by the U.S. Attorney’s Office, District of Massachusetts, relating to an investigation into possible federal health care offenses. The subpoena covered the period from January 1, 2007 to the present, and sought documents relevant to charitable patient assistance organizations, particularly the American Kidney Fund, including documents related to efforts to provide patients with information concerning the availability of charitable assistance. The Department of Justice notified the Court on July 23, 2019 of its decision to elect not to intervene in the matter of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">U.S. ex rel. David Gonzalez v. DaVita Healthcare Partners, et al</span><span style="font-family:inherit;font-size:10pt;">. The complaint then was unsealed in the U.S. District Court, District of Massachusetts by order entered on August 1, 2019. The Department of Justice has confirmed that the complaint, which alleges violations of the FCA and various </span></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">state false claims acts, was the basis of its investigation initiated in January 2017. The Company has not been served with the complaint.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">2017 U.S. Attorney Colorado Investigation</span><span style="font-family:inherit;font-size:10pt;">: In November 2017, the U.S. Attorney’s Office, District of Colorado informed the Company of an investigation it was conducting into possible federal healthcare offenses involving DaVita Kidney Care, as well as several of the Company’s wholly-owned subsidiaries. The matter currently includes an investigation into DaVita Rx, DaVita Laboratory Services, Inc. (DaVita Labs), and RMS Lifeline Inc. (Lifeline). In each of August 2018 and May 2019, the Company received a CID pursuant to the FCA from the U.S. Attorney's Office relating to this investigation. The Company is continuing to cooperate with the government in this investigation. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">2018 U.S. Attorney Florida Investigation</span><span style="font-family:inherit;font-size:10pt;">: In March 2018, DaVita Labs received two CIDs from the U.S. Attorney’s Office, Middle District of Florida that were identical in nature but directed to the two different labs. According to the face of the CIDs, the U.S. Attorney’s Office is conducting an investigation as to whether the Company’s subsidiary submitted claims for blood, urine, and fecal testing, where there were insufficient test validation or stability studies to ensure accurate results, in violation of the FCA. In October 2018, DaVita Labs received a subpoena from the OIG in connection with this matter requesting certain patient records linked to clinical laboratory tests. On September 30, 2019, the U.S. Attorney’s Office notified the U.S. District Court, Middle District of Florida, of its decision not to elect to intervene at this time in the matter of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">U.S. ex rel. Lorne Holland, et al. v. DaVita Healthcare Partners, Inc., et al</span><span style="font-family:inherit;font-size:10pt;">. The court then unsealed the complaint, which alleges violations of the FCA, by order dated the same day. The Company has not been served with the complaint.</span></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">* * *</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Although the Company cannot predict whether or when proceedings might be initiated or when these matters may be resolved (other than as may be described above), it is not unusual for inquiries such as these to continue for a considerable period of time through the various phases of document and witness requests and on-going discussions with regulators and to develop over the course of time. In addition to the inquiries and proceedings specifically identified above, the Company frequently is subject to other inquiries by state or federal government agencies and/or private civil </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">qui tam</span><span style="font-family:inherit;font-size:10pt;"> complaints filed by relators. Negative findings or terms and conditions that the Company might agree to accept as part of a negotiated resolution of pending or future government inquiries or relator proceedings could result in, among other things, substantial financial penalties or awards against the Company, substantial payments made by the Company, harm to the Company’s reputation, required changes to the Company’s business practices, exclusion from future participation in the Medicare, Medicaid and other federal health care programs and, if criminal proceedings were initiated against the Company, members of its board of directors or management, possible criminal penalties, any of which could have a material adverse effect on the Company.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Shareholder and Derivative Claims</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Peace Officers’ Annuity and Benefit Fund of Georgia Securities Class Action Civil Suit</span><span style="font-family:inherit;font-size:10pt;">: On February 1, 2017, the Peace Officers’ Annuity and Benefit Fund of Georgia filed a putative federal securities class action complaint in the U.S. District Court for the District of Colorado against the Company and certain executives. The complaint covers the time period of August 2015 to October 2016 and alleges, generally, that the Company and its executives violated</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"> </span><span style="font-family:inherit;font-size:10pt;">federal securities laws concerning the Company’s financial results and revenue derived from patients who received charitable premium assistance from an industry-funded non-profit organization. The complaint further alleges that the process by which patients obtained commercial insurance and received charitable premium assistance was improper and "created a false impression of DaVita’s business and operational status and future growth prospects." In November 2017, the court appointed the lead plaintiff and an amended complaint was filed on January 12, 2018. On March 27, 2018, the Company and various individual defendants filed a motion to dismiss. On March 28, 2019, the U.S. District Court for the District of Colorado denied the motion to dismiss. The Company answered the complaint on May 28, 2019. The Company disputes these allegations and intends to defend this action accordingly.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">In re DaVita Inc. Stockholder Derivative Litigation</span><span style="font-family:inherit;font-size:10pt;">: On August 15, 2017, the U.S. District Court for the District of Delaware consolidated </span><span style="font-family:inherit;font-size:10pt;"><span>three</span></span><span style="font-family:inherit;font-size:10pt;"> previously disclosed shareholder derivative lawsuits: the Blackburn Shareholder action filed on February 10, 2017, the Gabilondo Shareholder action filed on May 30, 2017, and the City of Warren Police and Fire Retirement System Shareholder action filed on June 9, 2017. The complaint covers the time period from 2015 to present and alleges, generally, breach of fiduciary duty, unjust enrichment, abuse of control, gross mismanagement, corporate waste, and misrepresentations and/or failures to disclose certain information in violation of the federal securities laws in connection with an alleged practice to direct patients with government-subsidized health insurance into private health insurance plans to </span></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">maximize the Company’s profits. An amended complaint was filed in September 2017, and on December 18, 2017, the Company filed a motion to dismiss and a motion to stay proceedings in the alternative. On April 25, 2019, the court denied the Company's motion to dismiss. The Company answered the complaint on May 28, 2019. The Company disputes these allegations and intends to defend this action accordingly. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other Proceedings</span></div><div style="line-height:120%;padding-top:12px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition to the foregoing, from time to time the Company is subject to other lawsuits, demands, claims, governmental investigations and audits and legal proceedings that arise due to the nature of its business, including, without limitation, contractual disputes, such as with payors, suppliers and others, employee-related matters and professional and general liability claims. From time to time, the Company also initiates litigation or other legal proceedings as a plaintiff arising out of contracts or other matters.</span></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">* * *</span></div><div style="line-height:120%;padding-top:12px;text-indent:37px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other than as may be described above, the Company cannot predict the ultimate outcomes of the various legal proceedings and regulatory matters to which the Company is or may be subject from time to time, including those described in this Note </span><span style="font-family:inherit;font-size:10pt;">11</span><span style="font-family:inherit;font-size:10pt;"> to these condensed consolidated financial statements, or the timing of their resolution or the ultimate losses or impact of developments in those matters, which could have a material adverse effect on the Company’s revenues, earnings and cash flows. Further, any legal proceedings or regulatory matters involving the Company, whether meritorious or not, are time consuming, and often require management’s attention and result in significant legal expense, and may result in the diversion of significant operational resources, or otherwise harm the Company’s business, results of operations, financial condition, cash flows or reputation.</span></div>
dva Longterm Incentive Program Compensation Cost
LongtermIncentiveProgramCompensationCost
82469000 USD
dva Longterm Incentive Program Compensation Cost
LongtermIncentiveProgramCompensationCost
74077000 USD
dva Employee Service Share Based Compensation Estimated Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense
6798000 USD
dva Employee Service Share Based Compensation Estimated Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense
10887000 USD
CY2019Q3 dva Longterm Incentive Program Awards Compensation Cost Not Yet Recognized Net
LongtermIncentiveProgramAwardsCompensationCostNotYetRecognizedNet
166502000 USD
CY2019Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
151805000 USD
dva Longterm Incentive Program Awards Compensation Cost Not Yet Recognized Period For Recognition
LongtermIncentiveProgramAwardsCompensationCostNotYetRecognizedPeriodForRecognition
P0Y7M6D
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y7M6D
us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
2791000 USD
us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
7919000 USD
CY2019Q3 us-gaap Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
30592000 shares
CY2019Q3 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
1747968000 USD
CY2019Q3 us-gaap Treasury Stock Acquired Average Cost Per Share
TreasuryStockAcquiredAverageCostPerShare
57.14
us-gaap Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
32652000 shares
us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
1860157000 USD
us-gaap Treasury Stock Acquired Average Cost Per Share
TreasuryStockAcquiredAverageCostPerShare
56.97
CY2019Q3 us-gaap Stock Repurchase Program Authorized Amount1
StockRepurchaseProgramAuthorizedAmount1
2000000000 USD
us-gaap Business Combination Consideration Transferred Liabilities Incurred
BusinessCombinationConsiderationTransferredLiabilitiesIncurred
19818000 USD
dva Business Combination Contingent Consideration Acquisitions
BusinessCombinationContingentConsiderationAcquisitions
35338000 USD
CY2018Q4 us-gaap Business Combination Contingent Consideration Arrangements Range Of Outcomes Value High
BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
2608000 USD
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-19731000 USD
dva Business Combination Contingent Consideration Acquisitions Fair Value Remeasurement Gain Loss
BusinessCombinationContingentConsiderationAcquisitionsFairValueRemeasurementGainLoss
2179000 USD
dva Business Combination Contingent Consideration Acquisitions Earnouts Payments
BusinessCombinationContingentConsiderationAcquisitionsEarnoutsPayments
327000 USD
CY2019Q3 us-gaap Business Combination Contingent Consideration Arrangements Range Of Outcomes Value High
BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
19833000 USD
CY2019Q2 us-gaap Proceeds From Divestiture Of Businesses
ProceedsFromDivestitureOfBusinesses
4465476000 USD
CY2019Q2 us-gaap Proceeds From Divestiture Of Businesses Net Of Cash Divested
ProceedsFromDivestitureOfBusinessesNetOfCashDivested
3824509000 USD
CY2019Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-6843000 USD
CY2018Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-211739000 USD
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
102854000 USD
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-147829000 USD
CY2019Q3 us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
97005000 USD
CY2018Q3 us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
208570000 USD
CY2019Q3 us-gaap Cash Provided By Used In Investing Activities Discontinued Operations
CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
-43442000 USD
CY2018Q3 us-gaap Cash Provided By Used In Investing Activities Discontinued Operations
CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
-32860000 USD
CY2019Q3 us-gaap Variable Interest Entity Consolidated Carrying Amount Assets
VariableInterestEntityConsolidatedCarryingAmountAssets
389284000 USD
CY2019Q3 us-gaap Variable Interest Entity Consolidated Carrying Amount Liabilities
VariableInterestEntityConsolidatedCarryingAmountLiabilities
273660000 USD
CY2019Q3 us-gaap Revenues
Revenues
2904078000 USD
CY2018Q3 us-gaap Revenues
Revenues
2847330000 USD
us-gaap Revenues
Revenues
8489895000 USD
us-gaap Revenues
Revenues
8583727000 USD
CY2019Q3 dva Segment Reporting Information Corporate Expenses
SegmentReportingInformationCorporateExpenses
24681000 USD
CY2018Q3 dva Segment Reporting Information Corporate Expenses
SegmentReportingInformationCorporateExpenses
40836000 USD
dva Segment Reporting Information Corporate Expenses
SegmentReportingInformationCorporateExpenses
65546000 USD
dva Segment Reporting Information Corporate Expenses
SegmentReportingInformationCorporateExpenses
70605000 USD
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
378336000 USD
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
289038000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
1180729000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
1137916000 USD
CY2019Q3 us-gaap Interest And Debt Expense
InterestAndDebtExpense
88589000 USD
CY2018Q3 us-gaap Interest And Debt Expense
InterestAndDebtExpense
125927000 USD
us-gaap Interest And Debt Expense
InterestAndDebtExpense
351774000 USD
us-gaap Interest And Debt Expense
InterestAndDebtExpense
359135000 USD
CY2019Q3 dva Debt Prepayment Refinancing Redemption Charges
DebtPrepaymentRefinancingRedemptionCharges
21242000 USD
CY2018Q3 dva Debt Prepayment Refinancing Redemption Charges
DebtPrepaymentRefinancingRedemptionCharges
0 USD
dva Debt Prepayment Refinancing Redemption Charges
DebtPrepaymentRefinancingRedemptionCharges
33402000 USD
dva Debt Prepayment Refinancing Redemption Charges
DebtPrepaymentRefinancingRedemptionCharges
0 USD
CY2019Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
5280000 USD
CY2018Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4007000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
17863000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
10583000 USD
CY2019Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
273785000 USD
CY2018Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
167118000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
813416000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
789364000 USD
CY2019Q3 us-gaap Assets
Assets
17451830000 USD
CY2018Q4 us-gaap Assets
Assets
19110252000 USD
CY2019Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
155915000 USD
CY2018Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
146000000 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
456685000 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
435878000 USD
CY2019Q3 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
173265000 USD
CY2018Q3 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
231682000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
547183000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
705659000 USD
CY2018Q3 us-gaap Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Changes Purchase Of Interest By Parent
ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent
5285000 USD
dva Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Changes Purchase Or Sale Of Interest By Parent
ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOrSaleOfInterestByParent
10732000 USD
CY2019Q3 us-gaap Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest
NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
143270000 USD
CY2018Q3 us-gaap Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest
NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
-136796000 USD
us-gaap Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest
NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
566110000 USD
us-gaap Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest
NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
309166000 USD
CY2019Q3 us-gaap Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Changes Sale Of Interest By Parent
ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesSaleOfInterestByParent
0 USD
CY2018Q3 us-gaap Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Changes Sale Of Interest By Parent
ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesSaleOfInterestByParent
0 USD
us-gaap Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Changes Sale Of Interest By Parent
ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesSaleOfInterestByParent
0 USD
us-gaap Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Changes Sale Of Interest By Parent
ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesSaleOfInterestByParent
79000 USD
CY2019Q3 us-gaap Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Changes Purchase Of Interest By Parent
ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent
202000 USD
us-gaap Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Changes Purchase Of Interest By Parent
ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent
17482000 USD
CY2019Q3 us-gaap Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Changes Net
ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNet
-202000 USD
CY2018Q3 us-gaap Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Changes Net
ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNet
-5285000 USD
us-gaap Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Changes Net
ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNet
10732000 USD
us-gaap Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Changes Net
ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNet
-17403000 USD
CY2019Q3 us-gaap Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Change Due To Net Income Attributable To Parent And Effects Of Changes Net
ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet
143068000 USD
CY2018Q3 us-gaap Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Change Due To Net Income Attributable To Parent And Effects Of Changes Net
ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet
-142081000 USD
us-gaap Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Change Due To Net Income Attributable To Parent And Effects Of Changes Net
ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet
576842000 USD
us-gaap Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Change Due To Net Income Attributable To Parent And Effects Of Changes Net
ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet
291763000 USD
us-gaap Description Of New Accounting Pronouncements Not Yet Adopted
DescriptionOfNewAccountingPronouncementsNotYetAdopted
<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">New accounting standards</span></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU No. 2016-02, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases (Topic 842)</span><span style="font-family:inherit;font-size:10pt;">. The amendments in Topic 842 revise the accounting related to lessee accounting. Under the new guidance, lessees are required to recognize a lease liability and a right-of-use asset for substantially all leases with lease terms in excess of twelve months. The new lease guidance also simplifies the accounting for sale and leaseback transactions primarily because lessees must recognize lease assets and lease liabilities. The Company adopted Topic 842 beginning on January 1, 2019 through a modified retrospective approach for leases existing at the </span></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">adoption date with a cumulative effect adjustment. The Company elected to apply the package of practical expedients to not recast prior conclusions related to contracts containing leases, lease classification and initial direct costs. Adoption of the new standard resulted in the recording of operating right-of-use assets of </span><span style="font-family:inherit;font-size:10pt;"><span>$2,783,784</span></span><span style="font-family:inherit;font-size:10pt;">, operating lease liabilities of </span><span style="font-family:inherit;font-size:10pt;"><span>$3,001,354</span></span><span style="font-family:inherit;font-size:10pt;"> and an adjustment to retained earnings of </span><span style="font-family:inherit;font-size:10pt;"><span>$39,876</span></span><span style="font-family:inherit;font-size:10pt;">, primarily related to deferred gains on prior sale leaseback transactions as of January 1, 2019. The standard did not materially impact the Company's consolidated net earnings and had </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> impact on cash flows. See Note </span><span style="font-family:inherit;font-size:10pt;">10</span><span style="font-family:inherit;font-size:10pt;"> to these condensed consolidated financial statements for further details.</span></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued ASU No. 2016-13, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. </span><span style="font-family:inherit;font-size:10pt;">The amendments in this ASU change the approach for recognizing credit losses on financial assets from the incurred loss methodology in current GAAP to a methodology that reflects current expected credit losses, which requires consideration of a broader range of reasonable and supportable information to inform those credit loss estimates. The current incurred loss model delays recognition of credit losses until it is probable that a loss has been incurred, while this ASU’s new current expected credit loss model requires estimation of credit losses expected over the life of the financial asset or group of similar financial assets. The amendments in this ASU are effective for the Company on January 1, 2020 and are to be applied on a modified-retrospective approach. The Company is still evaluating certain aspects of this ASU as well as the impacts it may have on its consolidated financial statements when adopted on January 1, 2020.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2017, the FASB issued ASU No. 2017-12, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities. </span><span style="font-family:inherit;font-size:10pt;">The amendments in this ASU better align an entity’s risk management activities and financial reporting for hedging relationships through changes to both the designation and measurement guidance for qualifying hedging relationships and the presentation of hedge results. The amendments in this ASU were effective for the Company on January 1, 2019 and are to be applied prospectively. The adoption of this ASU did not have a material impact on the Company’s consolidated financial statements when adopted on January 1, 2019.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2018, the FASB issued ASU No. 2018-13, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value Measurement (Topic 820): Disclosure Framework -Changes to the Disclosure Requirements for Fair Value Measurement</span><span style="font-family:inherit;font-size:10pt;">. The applicable amendments in this ASU remove requirements for disclosures concerning transfers between fair value measurement levels 1, 2 and 3 and disclosures concerning valuation processes for level 3 fair value measurements. The applicable amendments in this ASU also add a requirement to separately disclose the changes in unrealized gains and losses included in other comprehensive income for the reporting period for level 3 items measured at fair value on a recurring basis, and require disclosure of the range and weighted average of significant unobservable inputs used to develop level 3 fair value measurements. The amendments in this ASU are effective for the Company beginning on January 1, 2020 and its new requirements are to be applied on a prospective basis. The adoption of this ASU is not expected to have a material impact on the Company’s consolidated financial statements.</span></div>
CY2019Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
2781169000 USD
CY2019Q3 us-gaap Health Care Organization Patient Service Revenue Provisionfor Bad Debts
HealthCareOrganizationPatientServiceRevenueProvisionforBadDebts
3977000 USD
CY2019Q3 us-gaap Health Care Organization Patient Service Revenue Less Provision For Bad Debts
HealthCareOrganizationPatientServiceRevenueLessProvisionForBadDebts
2777192000 USD
CY2018Q3 us-gaap Health Care Organization Patient Service Revenue Provisionfor Bad Debts
HealthCareOrganizationPatientServiceRevenueProvisionforBadDebts
11977000 USD
CY2018Q3 us-gaap Health Care Organization Patient Service Revenue Less Provision For Bad Debts
HealthCareOrganizationPatientServiceRevenueLessProvisionForBadDebts
2658724000 USD
CY2018Q3 us-gaap Other Income
OtherIncome
188606000 USD
CY2018Q3 us-gaap Revenues
Revenues
2847330000 USD
CY2018Q3 us-gaap Costs And Expenses
CostsAndExpenses
2558292000 USD
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
289038000 USD
CY2018Q3 dva Debt Expense Including Debt Refinancing Charges
DebtExpenseIncludingDebtRefinancingCharges
125927000 USD
CY2018Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4007000 USD
CY2018Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
52047000 USD
CY2018Q3 dva Equity In Earnings Loss Of Consolidated Affiliates
EquityInEarningsLossOfConsolidatedAffiliates
0 USD
CY2018Q3 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
115071000 USD
us-gaap Costs And Expenses
CostsAndExpenses
7309166000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
1180729000 USD
dva Debt Expense Including Debt Refinancing Charges
DebtExpenseIncludingDebtRefinancingCharges
385176000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
17863000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
197938000 USD
dva Equity In Earnings Loss Of Consolidated Affiliates
EquityInEarningsLossOfConsolidatedAffiliates
0 USD
CY2019Q3 us-gaap Other Income
OtherIncome
126886000 USD
CY2019Q3 us-gaap Revenues
Revenues
2904078000 USD
CY2019Q3 us-gaap Costs And Expenses
CostsAndExpenses
2525742000 USD
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
378336000 USD
CY2019Q3 dva Debt Expense Including Debt Refinancing Charges
DebtExpenseIncludingDebtRefinancingCharges
109831000 USD
CY2019Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
5280000 USD
CY2019Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
65254000 USD
CY2019Q3 dva Equity In Earnings Loss Of Consolidated Affiliates
EquityInEarningsLossOfConsolidatedAffiliates
0 USD
CY2019Q3 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
208531000 USD
CY2019Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-6843000 USD
CY2019Q3 us-gaap Profit Loss
ProfitLoss
201688000 USD
CY2019Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
58418000 USD
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
143270000 USD
CY2018Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
2670701000 USD
CY2018Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-211739000 USD
CY2018Q3 us-gaap Profit Loss
ProfitLoss
-96668000 USD
CY2018Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
40128000 USD
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-136796000 USD
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
8150386000 USD
us-gaap Health Care Organization Patient Service Revenue Provisionfor Bad Debts
HealthCareOrganizationPatientServiceRevenueProvisionforBadDebts
19689000 USD
us-gaap Health Care Organization Patient Service Revenue Less Provision For Bad Debts
HealthCareOrganizationPatientServiceRevenueLessProvisionForBadDebts
8130697000 USD
us-gaap Other Income
OtherIncome
359198000 USD
us-gaap Revenues
Revenues
8489895000 USD
us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
615478000 USD
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
102854000 USD
us-gaap Profit Loss
ProfitLoss
718332000 USD
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
152222000 USD
us-gaap Net Income Loss
NetIncomeLoss
566110000 USD
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
7980178000 USD
us-gaap Health Care Organization Patient Service Revenue Provisionfor Bad Debts
HealthCareOrganizationPatientServiceRevenueProvisionforBadDebts
35838000 USD
us-gaap Health Care Organization Patient Service Revenue Less Provision For Bad Debts
HealthCareOrganizationPatientServiceRevenueLessProvisionForBadDebts
7944340000 USD
us-gaap Other Income
OtherIncome
639387000 USD
us-gaap Revenues
Revenues
8583727000 USD
us-gaap Costs And Expenses
CostsAndExpenses
7445811000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
1137916000 USD
dva Debt Expense Including Debt Refinancing Charges
DebtExpenseIncludingDebtRefinancingCharges
359135000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
10583000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
206652000 USD
dva Equity In Earnings Loss Of Consolidated Affiliates
EquityInEarningsLossOfConsolidatedAffiliates
0 USD
us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
582712000 USD
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-147829000 USD
us-gaap Profit Loss
ProfitLoss
434883000 USD
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
125717000 USD
us-gaap Net Income Loss
NetIncomeLoss
309166000 USD
CY2019Q3 us-gaap Profit Loss
ProfitLoss
201688000 USD
CY2019Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-43993000 USD
CY2019Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
157695000 USD
CY2019Q3 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
58418000 USD
CY2019Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
99277000 USD
CY2018Q3 us-gaap Profit Loss
ProfitLoss
-96668000 USD
CY2018Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-7184000 USD
CY2018Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-103852000 USD
CY2018Q3 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
40128000 USD
CY2018Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-143980000 USD
us-gaap Profit Loss
ProfitLoss
718332000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-42680000 USD
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
675652000 USD
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
152222000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
523430000 USD
us-gaap Profit Loss
ProfitLoss
434883000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-33976000 USD
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
400907000 USD
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
125717000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
275190000 USD
CY2019Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1253256000 USD
CY2019Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
103885000 USD
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
323038000 USD
CY2018Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
92382000 USD
CY2018Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1858608000 USD
CY2018Q4 dva Investments And Other Current Assets
InvestmentsAndOtherCurrentAssets
760566000 USD
CY2018Q4 us-gaap Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
5389565000 USD
CY2018Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
3908398000 USD
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
19110252000 USD
CY2018Q4 us-gaap Assets Current
AssetsCurrent
8424159000 USD
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3393669000 USD
CY2018Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
118846000 USD
CY2018Q4 dva Investments In And Advances To Affiliates Net
InvestmentsInAndAdvancesToAffiliatesNet
0 USD
CY2019Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1901225000 USD
CY2019Q3 dva Investments And Other Current Assets
InvestmentsAndOtherCurrentAssets
740352000 USD
CY2019Q3 us-gaap Assets Current
AssetsCurrent
3998718000 USD
CY2019Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3419238000 USD
CY2019Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2781288000 USD
CY2019Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
117666000 USD
CY2019Q3 dva Investments In And Advances To Affiliates Net
InvestmentsInAndAdvancesToAffiliatesNet
0 USD
CY2019Q3 us-gaap Investments And Other Noncurrent Assets
InvestmentsAndOtherNoncurrentAssets
369261000 USD
CY2019Q3 us-gaap Goodwill
Goodwill
6765659000 USD
CY2019Q3 us-gaap Assets
Assets
17451830000 USD
CY2019Q3 dva Current Liabilities
CurrentLiabilities
2206640000 USD
CY2019Q3 us-gaap Due To Related Parties Noncurrent
DueToRelatedPartiesNoncurrent
0 USD
CY2019Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2682125000 USD
CY2019Q3 dva Long Term Debt And Other Noncurrent
LongTermDebtAndOtherNoncurrent
8754483000 USD
CY2019Q3 us-gaap Redeemable Noncontrolling Interest Equity Carrying Amount
RedeemableNoncontrollingInterestEquityCarryingAmount
1296059000 USD
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
2318576000 USD
CY2019Q3 us-gaap Minority Interest
MinorityInterest
193947000 USD
CY2019Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
2512523000 USD
CY2019Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
17451830000 USD
CY2018Q4 us-gaap Investments And Other Noncurrent Assets
InvestmentsAndOtherNoncurrentAssets
331618000 USD
CY2018Q4 us-gaap Goodwill
Goodwill
6841960000 USD
CY2018Q4 us-gaap Assets
Assets
19110252000 USD
CY2018Q4 dva Current Liabilities
CurrentLiabilities
3647402000 USD
CY2018Q4 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
1243759000 USD
CY2018Q4 us-gaap Due To Related Parties Noncurrent
DueToRelatedPartiesNoncurrent
0 USD
CY2018Q4 dva Long Term Debt And Other Noncurrent
LongTermDebtAndOtherNoncurrent
9186052000 USD
CY2018Q4 us-gaap Redeemable Noncontrolling Interest Equity Carrying Amount
RedeemableNoncontrollingInterestEquityCarryingAmount
1124641000 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
3703442000 USD
CY2018Q4 us-gaap Minority Interest
MinorityInterest
204956000 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-423339000 USD
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-5790000 USD
us-gaap Profit Loss
ProfitLoss
718332000 USD
us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
673493000 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
1391825000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
547183000 USD
us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
77348000 USD
us-gaap Proceeds From Sales Of Business Affiliate And Productive Assets
ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets
3863619000 USD
dva Payments For Proceeds From Sale Of Investments In Securities And Other
PaymentsForProceedsFromSaleOfInvestmentsInSecuritiesAndOther
105063000 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
3134025000 USD
dva Proceeds From Repayments Of Long Term Debt
ProceedsFromRepaymentsOfLongTermDebt
-2050012000 USD
us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
0 USD
dva Payments For Other Financing Activities
PaymentsForOtherFinancingActivities
1953752000 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-4003764000 USD
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-4178000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
517908000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
415420000 USD
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1357141000 USD
us-gaap Profit Loss
ProfitLoss
434883000 USD
us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
947365000 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
1382248000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
705659000 USD
us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
113526000 USD
us-gaap Proceeds From Sales Of Business Affiliate And Productive Assets
ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets
135268000 USD
dva Payments For Proceeds From Sale Of Investments In Securities And Other
PaymentsForProceedsFromSaleOfInvestmentsInSecuritiesAndOther
-22598000 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-661319000 USD
dva Proceeds From Repayments Of Long Term Debt
ProceedsFromRepaymentsOfLongTermDebt
845836000 USD
us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
0 USD
dva Payments For Other Financing Activities
PaymentsForOtherFinancingActivities
1269175000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
291800000 USD
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
518920000 USD
CY2018Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
540155000 USD
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
8150386000 USD
us-gaap Health Care Organization Patient Service Revenue Provisionfor Bad Debts
HealthCareOrganizationPatientServiceRevenueProvisionforBadDebts
19689000 USD
us-gaap Health Care Organization Patient Service Revenue Less Provision For Bad Debts
HealthCareOrganizationPatientServiceRevenueLessProvisionForBadDebts
8130697000 USD
us-gaap Other Income
OtherIncome
359198000 USD
us-gaap Revenues
Revenues
8489895000 USD
us-gaap Costs And Expenses
CostsAndExpenses
7309166000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
1180729000 USD
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
102854000 USD
dva Debt Expense Including Debt Refinancing Charges
DebtExpenseIncludingDebtRefinancingCharges
385176000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
17863000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
197938000 USD
us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
615478000 USD
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
2318576000 USD
CY2019Q3 us-gaap Minority Interest
MinorityInterest
193947000 USD
CY2019Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
2512523000 USD
CY2019Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
17451830000 USD
us-gaap Profit Loss
ProfitLoss
718332000 USD
us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
673493000 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
1391825000 USD
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-4178000 USD
us-gaap Profit Loss
ProfitLoss
718332000 USD
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
152222000 USD
us-gaap Net Income Loss
NetIncomeLoss
566110000 USD
us-gaap Profit Loss
ProfitLoss
718332000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-42680000 USD
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
675652000 USD
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
152222000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
523430000 USD
CY2019Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1253256000 USD
CY2019Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
103885000 USD
CY2019Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1901225000 USD
CY2019Q3 dva Investments And Other Current Assets
InvestmentsAndOtherCurrentAssets
740352000 USD
CY2019Q3 us-gaap Assets Current
AssetsCurrent
3998718000 USD
CY2019Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3419238000 USD
CY2019Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2781288000 USD
CY2019Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
117666000 USD
CY2019Q3 us-gaap Investments And Other Noncurrent Assets
InvestmentsAndOtherNoncurrentAssets
369261000 USD
CY2019Q3 us-gaap Goodwill
Goodwill
6765659000 USD
CY2019Q3 us-gaap Assets
Assets
17451830000 USD
CY2019Q3 dva Current Liabilities
CurrentLiabilities
2206640000 USD
CY2019Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2682125000 USD
CY2019Q3 dva Long Term Debt And Other Noncurrent
LongTermDebtAndOtherNoncurrent
8754483000 USD
CY2019Q3 us-gaap Redeemable Noncontrolling Interest Equity Carrying Amount
RedeemableNoncontrollingInterestEquityCarryingAmount
1296059000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
547183000 USD
us-gaap Payments For Proceeds From Businesses And Interest In Affiliates
PaymentsForProceedsFromBusinessesAndInterestInAffiliates
77348000 USD
us-gaap Proceeds From Sales Of Business Affiliate And Productive Assets
ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets
3863619000 USD
dva Payments For Proceeds From Sale Of Investments In Securities And Other
PaymentsForProceedsFromSaleOfInvestmentsInSecuritiesAndOther
105063000 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
3134025000 USD
dva Proceeds From Repayments Of Long Term Debt
ProceedsFromRepaymentsOfLongTermDebt
-2050012000 USD
us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
0 USD
dva Payments For Other Financing Activities
PaymentsForOtherFinancingActivities
1953752000 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-4003764000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
517908000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
415420000 USD
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1357141000 USD

Files In Submission

Name View Source Status
0000927066-19-000176-index-headers.html Edgar Link pending
0000927066-19-000176-index.html Edgar Link pending
0000927066-19-000176.txt Edgar Link pending
0000927066-19-000176-xbrl.zip Edgar Link pending
dva-20190930.xsd Edgar Link pending
dva-20190930_cal.xml Edgar Link unprocessable
dva-20190930_def.xml Edgar Link unprocessable
dva-20190930_lab.xml Edgar Link unprocessable
dva-20190930_pre.xml Edgar Link unprocessable
dva-9301910q.htm Edgar Link pending
dva-9301910q_htm.xml Edgar Link completed
dva-93019ex311.htm Edgar Link pending
dva-93019ex312.htm Edgar Link pending
dva-93019ex321.htm Edgar Link pending
dva-93019ex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
logoa27.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R83.htm Edgar Link pending
R84.htm Edgar Link pending
R85.htm Edgar Link pending
R86.htm Edgar Link pending
R87.htm Edgar Link pending
R88.htm Edgar Link pending
R89.htm Edgar Link pending
R9.htm Edgar Link pending
R90.htm Edgar Link pending
R91.htm Edgar Link pending
R92.htm Edgar Link pending
R93.htm Edgar Link pending
R94.htm Edgar Link pending
R95.htm Edgar Link pending
R96.htm Edgar Link pending
R97.htm Edgar Link pending
R98.htm Edgar Link pending
R99.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending